Hospira Recalls Diazepam Injection Vials Due to Sterility Concerns
Hospira Inc. is recalling 95,700 vials of Diazepam Injection due to a loose crimp on the fliptop vial, which compromises sterility assurance.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class II. According to the rubric, FDA Class II recalls with potential for adverse health consequences (such as sterility issues in injectable drugs) are categorized as Severe (Score 4), particularly when no specific hospitalization reports are cited but the defect is structural/sterility-related.
Plain-English summary
Hospira Inc. is recalling 95,700 vials of Diazepam Injection, USP 5 mg/mL, 10 mL, Multiple-dose fliptop vial. The recall is due to a lack of assurance of sterility caused by a loose crimp applied to the fliptop vial. The affected product is identified by lot number 17-099-EV and has an expiration date of 05/14.
The recalled product was distributed nationwide and in Puerto Rico. The FDA has classified this recall as Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Healthcare providers and patients should stop using the affected vials and contact Hospira Inc. or their local FDA office for further instructions on returning the product.
The recalled product
- Product
- DIAZEPAM (DIAZEPAM)
- Brand
- DIAZEPAM
- Manufacturer
- Hospira Inc.
- Category
- Drug — Injectable
- Hazard
- Affected units
- 95,700
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 17-099-EV Exp 05/14
Distribution
Related recalls
Same brand · DIAZEPAM
- LowValeant Recalls Diazepam Rectal Gel Due to Missing Lot and Expiration Dates
FDA (Drugs) · 2018-08-15
- SevereHospira Recalls Diazepam Injection Due to Crystallized Active Ingredient
FDA (Drugs) · 2016-07-20
- SevereHospira Recalls Diazepam Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2013-09-04
- SevereHospira Recalls Diazepam Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-05-15
- SevereHospira Recalls Diazepam Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2013-05-08
Same manufacturer · Hospira Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29